Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rios-Perez, Jorge
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)	Recruiting	3	756	Europe, US, RoW	Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab	Shanghai Junshi Bioscience Co., Ltd.	Limited-stage Small Cell Lung Cancer (LS-SCLC)	07/27	07/29
NCT04984811: NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	2	83	US	efineptakin alfa, NT-I7, Atezolizumab, Tecentriq	NeoImmuneTech, Roche Pharma AG	Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer	09/24	03/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rios-Perez, Jorge
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)	Recruiting	3	756	Europe, US, RoW	Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab	Shanghai Junshi Bioscience Co., Ltd.	Limited-stage Small Cell Lung Cancer (LS-SCLC)	07/27	07/29
NCT04984811: NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	2	83	US	efineptakin alfa, NT-I7, Atezolizumab, Tecentriq	NeoImmuneTech, Roche Pharma AG	Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer	09/24	03/25